Tarsus Pharmaceuticals (TARS) Receivables (2020 - 2026)

Tarsus Pharmaceuticals' Receivables history runs 7 years deep, the most recent figure standing at $117.2 million for Q1 2026.

• On a quarterly basis, Receivables rose 82.7% year-over-year to $117.2 million in Q1 2026; TTM through Mar 2026 was $117.2 million, a 82.7% increase from a year earlier, with the FY2025 full-year figure at $87.1 million, up 81.25% from the prior year.
• Receivables improved to $117.2 million in Q1 2026 per TARS's latest filing, from $85.4 million in the prior quarter.
• Across five years, Receivables topped out at $117.2 million in Q1 2026 and bottomed at -$665000.0 in Q1 2023.
• The 5-year median for Receivables is $30.6 million (2024), against an average of $35.7 million.
• Across the five-year window, Receivables surged 7886.96% in 2022 and slumped 305.88% in 2023, its largest moves.
• Year by year, Receivables stood at $3.6 million in 2022, then soared by 366.36% to $16.7 million in 2023, then soared by 180.84% to $46.9 million in 2024, then soared by 82.02% to $85.4 million in 2025, then jumped by 37.26% to $117.2 million in 2026.
• Per Business Quant, the three latest TARS Receivables figures stand at $117.2 million (Q1 2026), $85.4 million (Q4 2025), and $74.3 million (Q3 2025).